ABL1 Fusion
Methodology
Molecular
Test Description and clinical significance
Genes
ABL1
Disease:
Chronic myeloid Leukemia, B-cell acute lymphoblastic leukemia and very rarely in acute myeloid leukemia.
Next generation sequencing of gene panel. ABL1 is most relevant to cancer in its role in the BCR-ABL fusion protein that has become a signature of chronic myeloid leukemia (CML). Cells harboring this fusion have shown sensitivity to imatinib, greatly improving the prognostic outlook of the disease. However, additional mutations in ABL1 have been shown to confer resistance to imatinib. In these resistance cases, second-generation tyrosine kinase inhibitors such as dasatinib and nilotinib have exhibited some efficacy and are currently undergoing clinical trials for treating acquired resistance in CML.
Specimen Requirements
Collection:
3 mL of EDTA, citrate (ACD) or Heparinized bone marrow and peripheral blood specimens for RNA gene fusion detection
At least 0.5 ml EDTA, citrate (ACD) or Heparinized whole blood or bone marrow aspirates for DNA mutations
Stability:
96hours/4 to 7 days refrigerated
Unacceptable Conditions:
Specimen submitted is in the incorrect fixative or anticoagulant. Specimen received after the stability date. Gross hemolysis. Frozen specimen. Insufficient specimen. Unlabeled. Left un-refrigerated for an extended period.
Storage & Transport
received within 96 hours of drawing. Samples that are 4 to 7 days old should be refrigerated.
CPT(s)
81170
New York Approved
NO
TAT
10 Days
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
